Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs

Expert Opinion on Investigational Drugs

Volumn 14, Issue 8, 2005, Pages 1019-1031

  Santos, Robson A S ^a   Ferreira, Anderson J ^a   Pinheiro, Sérgio V B ^a   Sampaio, Walkyria O ^a   Touyz, Rhian ^b   Campagnole Santos, Maria José ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

A 779; ACE inhibitors; Angiotensin inhibitors; Angiotensin (1 7) receptor Mas; Blood pressure; Renin angiotensin system

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7] AGONIST; AVE 0991; BENAZEPRILAT; CANDESARTAN; CAPTOPRIL; CARDIAC AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; LOSARTAN; PROTEIN MAS; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HEART INFARCTION; HEART VENTRICLE FAILURE; HORMONE ACTION; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION;

ANGIOTENSIN I; ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, ANGIOTENSIN;

EID: 23644452353     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.8.1019     Document Type: Review

References (123)

1. MOSTERD A, D'AGOSTINO RB, SILBERSHATZ H et al.: Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. New Engl. J. Med. (1999) 340(16):1221-1227.
2. BURNIER M, BRUNNER HR: Angiotensin II receptor antagonists. Lancet (2000) 355(9204):637-645.
3. ZAMAN MA, OPARIL S, CALHOUN DA: Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. (2002) 1(8):621-636.
4. CAREY RM, SIRAGY HM: Newly recognized components of the reninangiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. (2003) 24(3):261-271.
5. TALLANT EA, CHAPPELL MC, FERRARIO CM, GALLAGHER PE: Inhibition of MAP kinase activity by angiotensin-(1-7) in vascular smooth muscle cells is mediated by the Mas receptor. Hypertension (2004) 43(6):1348.
6. FERRARIO CM, CHAPPELL MC, TALLANT FA, BROSNIHAN KB, DIZ DI: Counterregulatory actions of angiotensin-(1-7). Hypertension (1997) 30(3 Part 2):535-541.
7. SANTOS RAS, CAMPAGNOLE-SANTOS MJ, ANDRADE SP: Angiotensin-(1-7): an update. Regul. Pept. (2000) 91:45-62.
8. VICKERS C, HALES P, KAUSHIK V et al.: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. (2002) 277(17):14838-14843.
9. SANTOS RAS, SIMOES E SILVA AC, MARIC C et al.: Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA (2003) 100:8258-8263.
10. SIGMUND CD: Genetic manipulation of the renin-angiotensin system: targeted expression of the renin-angiotensin system in the kidney. Am. J. Hypertens. (2001) 14(6 Part 2):33S-37S.
11. SCHMAIER AH: The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am. J. Physiol. (2003) 285(1):R1-R13.
12. CAMPBELL DJ: The renin-angiotensin and the kallikrein-kinin systems. Int. J. Biochem. Cell Biol. (2003) 35(6):784-791.
13. REUDELHUBER TL: The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr. Opin. Nephrol. Hypertens. (2005) 14(2):155-159.
14. TIPNIS SR, HOOPER NM, HYDE R, KARRAN E, CHRISTIE G, TURNER AJ: A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypepridase. J. Biol. Chem. (2000) 275(43):33238-33243.
15. DONOGHUE M, HSIEH F, BARONAS E et al.: A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. (2000) 87(5):E1-E9.
16. BROSNIHAN KB, LI P, FERRARIO CM: Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension (1996) 27(3 Part 2):523-528.
17. FERREIRA AJ, SANTOS RAS, ALMEIDA AP: Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension (2001) 38(Part 2):665-668.
18. LOOT AE, ROKS AJM, HENNING RH et al.: Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation (2002) 105:1548-1550.
19. SANTOS RAS, BRUM JM, BROSNIHAN KB, FERRARIO CM: The renin-angiotensin system during acute myocardial ischemia in dogs. Hypertension (1990) 15(Suppl. 2):1121-1127.
20. NEVES LAA, ALMEIDA AP, KHOSLA MC, SANTOS RAS: Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Biochem. Pharmacol. (1995) 50(9):1451-1459.
21. MAHMOOD A, JACKMAN HL, TEPLITZ L, IGIC R: Metabolism of angiotensin I in the coronary circulation of normal and diabetic rats. Peptides (2002) 23(6):1171-1175.
22. ZISMAN LS, MEIXELL GE, BRISTOW MR, CANVER CC: Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation (2003) 108(14):1679-1681.
23. BURRELL LM, JOHNSTON CI, TIKELLIS C, COOPER ME: ACE2, a new regulator of the renin-angiotensin system. Trends Endocrin. Met. (2004) 15(4):166-169.
24. RICE GI, THOMAS DA, GRANT PJ, TURNER AJ, HOOPER NM: Evaluation of angiotensin converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem. J. (2004) 383(Part 1):45-51.
25. OUDIT GY, CRACKOWER MA, BACKX PH, PENNINGER JM: The role of ACE2 in cadiovascular physiology. Trends Cardiovasc. Med. (2003) 13:93-101.
26. CRACKOWER MA, SARAO R, OUDIT GY et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 417(6891):822-828.
27. GURLEY SB, ALLRED A, LE TH et al.: Altered blood pressure response and normal cardiac phenotype in ACE2-deficient mice. Hypertension (2004) 44(4):501.
28. ZISMAN LS, KELLER RS, WEAVER B et al.: Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for up regulation of the angiotensin-converting enzyme homologue ACE2. Circulation (2003) 108(14):1707-1712.
29. GOULTER AB, GODDARD MJ, ALLEN JC, CLARK KL: ACE2 gene expression is up-regulated in the human failing heart. BMC Med. (2004) 2(1):19.
30. BURRELL LM, RISVANIS J, KUBOTA E et al.: Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. (2005) 26(4):369-375.
31. ISHIYAMA Y, GALLAGHER PE, AVERILL DB, TALLANT EA, BROSNIHAN KB, FERRARIO CM: Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. (2004) 43(5):970-976.
32. AVERILL DB, ISHIYAMA Y, CHAPPELL MC, FERRARIO CM: Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation (2003) 106(17):2141-2146.
33. ALMEIDA AP, FRÁBREGAS BC, MADUREIRA MM, SANTOS RJS, CAMPAGNOLE-SANTOS MJ, SANTOS RAS: Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz. J. Med. Biol. Res. (2000) 33:709-713.
34. PORSTI I, BARA AT, BUSSE R, HECKER M: Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br. J. Pharmacol. (1994) 111(3):652-654.
35. NEVES LAA, ALMEIDA AP, KHOSLA MC, CAMPAGNOLE-SANTOS MJ, SANTOS RAS: Effect of angiotensin-(1-7) on reperfusion arrhythmias in isolated rat hearts. Braz. J. Med. Biol. Res. (1997) 30:801-809.
36. KUMAGAI H, KHOSLA M, FERRARIO CM, FOUAD-TARAZI FM: Biological activity of angiotensin-(1-7) heptapeptide in the hamster heart. Hypertension (1990) 15(2 Suppl.):I29-I33.
37. SAMPAIO WO, NASCIMENTO AA, SANTOS RAS: Systemic and regional hemodynamics effects of angiotensin-(1-7) in rats. Am. J. Physiol. (2003) 284:H1985-H1994.
38. FERREIRA AJ, SANTOS RAS, ALMEIDA AP: Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Braz. J. Med. Biol. Res. (2002) 35:1083-1090.
39. DONOGHUE M, WAKIMOTO H, MAGUIRE CT et al.: Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J. Mol. Cell. Cardiol. (2003) 35(9):1043-1053.
40. OUDOT A, VERGELY C, ECARNOT-LAUBRIET A, ROCHETTE L: Pharmacological concentration of angiotensin-(1-7) activates NADPH oxidase after ischemia-reperfusion in rat heart through AT1 receptor stimulation. Regul. Pept. (2005) 127(1-3): 101-110.
41. METHOT D, VAN KATS JP, LOCHARD N, TREMBLAY F, SILVERSIDES DW, REUDELHUBER TL: Development and application of a biological peptide pump for the study of the in vivo actions of angiotensin peptides. Am. J. Hypertens. (2001) 14(6 Part 2):38S-43S.
42. SANTOS RAS, FERREIRA AJ, NADU AP et al.: Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprorective effects in rats. Physiol. Genomics (2004) 17(3):292-299.
43. SANTOS RAS, BROSNIHAN KB, JACOBSEN DW, DICORLETO PE, FERRARIO CM: Production of angiotensin-(1-7) by human vascular endothelium. Hypertension (1992) 19(Suppl. 2):II56-II61.
44. CHAPPELL MC, PIRRO NT, SYKES A, FERRARIO CM: Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension (1998) 31(1 Part 2):362-367.
45. FETERIK K, SMITH L, KATUSIC ZS: Angiotensin-(1-7) causes endothelium-dependent relaxation in canine middle cerebral artery. Brain Res. (2000) 873(1):75-82.
46. MENG W, BUSIJA DW: Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke (1993) 24(12):2041-2044.
47. OSEI SY, AHIMA RS, MINKES RK, WEAVER JP, KHOSLA MC, KADOWITZ PJ: Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur. J. Pharmacol. (1993) 234(1):35-42.
48. REN Y, GARVIN JL, CARRETERO AO: Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension (2002) 39(3):799-802.
49. LE TRAN Y, FORSTER C: Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J. Cardiovasc. Pharmacol. (1997) 30(5):676-682.
50. MACHADO RD, FERREIRA MA, BELO AV, SANTOS RAS, ANDRADE SP: Vasodilator effect of angiotensin-(1-7) in mature and sponge-induced neovasculature. Regul. Pept. (2002) 107(1-3):105-113.
51. OLIVEIRA MA, FORTES ZB, SANTOS RAS, KHOSLA MC, CARVALHO MHC: Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides (1999) 20:1195-1201.
52. FERNANDES L, FORTES ZB, NIGRO D, TOSTES RCA, SANTOS RAS, CARVALHO MHC: Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studies in vivo. Hypertension (2001) 37:703-709.
53. ROKS AJ, VAN GEEL PP, PINTO YM et al.: Angiotensin-(1-7) is a modulator of the human renin-angiotens in system. Hypertension (1999) 34(2):296-301.
54. SASAKI S, HIGASHI Y, NAKAGAWA K, MATSUURA H, KAJIYAMA G, OSHIMA T: Angiotensin-(1-7) induces endothelium-independent vasodilation in normotensive control subjects and essential hypertensive patients. Hypertension (2001) 38:90-94.
55. DAVIE AP, McMURRAY JJ: Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension (1999) 34(3):457-460.
56. IYER SN, FERRARIO CM, CHAPPELL MC: Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension (1998) 31(1 Part 2):356-361.
57. IYER SN, CHAPPELL MC, AVERILL DB, DIZ DI, FERRARIO CM: Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension (1998) 31(2):699-705.
58. COLLISTER JP, HENDEL MD: The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J. Renin Angiotensin Aldosterone Syst. (2003) 4(3):176-179.
59. HEITSCH H, BROVKOVYCH S, MALINSK T, WIEMER G: Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension (2001) 37:72-76.
60. LI P, CHAPPELL MC, FERRARIO CM, BROSNIHAN KB: Angiotensin-(1-7) augments bradikinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension (1997) 29:394-400.
61. MUTHALIF MM, BENTER IF, UDDIN MR, HAPER JL, MALIK KU: Signal transduction mechanism involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth cells. J. Pharmacol. Exp. Ther. (1998) 284:388-398.
62. GORELIK G, CARBINI LA, SCICLI AG: Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. J. Pharmacol. Exp. Ther. (1998) 286(1):403-410.
63. SOARES DE MOURA R, RESENDE AC, EMILIANO AF et al.: The role of bradykinin, AT2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. Br. J. Pharmacol. (2004) 141(5):860-866.
64. PAULA RD, LIMA CV, KHOSLA MC, SANTOS RAS: Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension (1995) 26(6 Part 2):1154-1159.
65. LIMA CV, PAULA RD, RESENDE FL, KHOSLA MC, SANTOS RAS: Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension (1997) 30(3 Part 2):542-548.
66. TOM B, DE VRIES R, SAXENA PR, DANSER AH: Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension (2001) 38(1):95-99.
67. HECKER M, BLAUKAT A, BARA AT, MULLER-ESTERL W, BUSSE R: ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br. J. Pharmacol. (1997) 121(7):1475-1481.
68. UEDA S, MASUMORI-MAEMOTO S, WADA A, ISHII M, BROSNIHAN KB, UMEMURA S: Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J. Hypertens. (2001) 19(11):2001-2009.
69. WILSDORF T, GAINER JV, MURPHEY LJ, VAUGHAN DE, BROWN NJ: Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension (2001) 37(4):1136-1140.
70. ERDOS EG, JACKMAN HL, BROVKOVYCH V, TAN F, DEDDISH PA: Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J. Mol. Cell. Cardiol. (2002) 34(12):1569-1576.
71. MAIA LG, RAMOS MC, FERNANDES L, CARVALHO MH, CAMPAGNOLE-SANTOS MJ, SANTOS RAS: Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J. Cardiovasc. Pharmacol. (2004) 43(5):685-691.
72. FREEMAN EJ, CHISOLM GM, FERRARIO CM, TALLANT EA: Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension (1996) 28(1):104-108.
73. MIN L, SIM MK, XU XG: Effects of desaspartate-angiotensin I on angiotensin II-induced incorporation of phenylalanine and thymidine in cultured rat cardiomyocytes and aortic smooth muscle cells. Regul. Pept. (2000) 95 (1-3):93-97.
74. MACHADO RD, SANTOS RAS, ANDRADE SP: Opposing actions of angiotensins on angiogenesis. Life Sci. (2000) 66(1):67-76.
75. ZHONG J, ZHU ZM, YANG YJ: Inhibition of PKC and ERK1/2 in cultured rat vascular smooth muscle cells by angiotensin-(1-7). Sheng Li Xue Bao (2001) 53(5):361-363.
76. LANGEVELD B, VAN GILST WH, TIO RA, ZIJLSTRA F, ROKS AJ: Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension (2005) 45(1):138-141.
77. SCHIAVONE MT, SANTOS RAS, BROSNIHAN KB, KHOSLA MC, FERRARIO CM: Release of vasopressin from the rat hypothalamoneurohypophysial system by angiotensin-(1-7) heptapeptide. Proc. Natl. Acad. Sci. USA (1988) 85:4095-4098.
78. CAMPAGNOLE-SANTOS MJ, HERINGER SB, BATISTA EN, KHOSLA MC, SANTOS RAS: Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am. J. Physiol. (1992) 263(1):R89-R94.
79. OLIVEIRA DR, SANTOS RAS, SANTOS GFP, KHOSLA MC, CAMPAGNOLE-SANTOS MJ: Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension (1996) 27:1284-1290.
80. BRITTO RR, SANTOS RAS, FAGUNDES-MOURA CR, KHOSLA MC, CAMPAGNOLE-SANTOS MJ: Role of angiotensin-(1-7) in the modulation of the baroreflex in renovascular hypertensive rats. Hypertension (1997) 30(3 Part 2):549-556.
81. HERINGER-WALTHER S,BATISTA EN, WALTHER T, KHOSLA MC, SANTOS RAS, CAMPAGNOLE-SANTOS MJ: Baroreflex improvement in SHR after ACE inhibition involves angiotensin-(1-7). Hypertension (2001) 37(5):1309-1314.
82. CHAVES GZ, CALIGIORNE SM, SANTOS RAS, KHOSLA MC, CAMPAGNOLE-SANTOS MJ: Modulation of the baroreflex control of heart rate by angiotensin-(1-7) at the nucleus tractus solitarii of normotensive and spontaneously hypertensive rats. J. Hypertens. (2000) 18(12):1841-1848.
83. FONTES MAP, MARTINS PINGE MC, NAVES V et al.: Cardiovascular effects produced by microinjection of angiotensins and angiotensin antagonists into the ventrolateral medulla of freely moving rats. Brain Res. (1997) 750:305-310.
84. ALZAMORA AC, SANTOS RAS, CAMPAGNOLE-SANTOS MJ: Hypotensive effect of ANG II and ANG-(1-7) at the caudal ventrolateral medulla involves different mechanisms. Am. J. Physiol. (2002) 283(5):R1187-R1195.
85. SANTOS RAS, CAMPAGNOLE-SANTOS MJ, BARACHO NCV et al.: Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res. Bull. (1994) 35(4):293-298.
86. HIROOKA Y, POTTS PD, DAMPNEY RAL: Role of angiotensin II receptor subtypes in mediating the sympathoexcitatory effects of exogenous and endogenous angiotensin peptides in the rostral ventrolateral medulla of the rabbit. Brain Res. (1997) 772:107-114.
87. HALL JE: The renin-angiotensin system: renal actions and blood pressure regulation. Compr. Ther. (1991) 17(5):8-17.
88. LARA LS, BICA RB, SENA SL et al.: Angiotensin-(1-7) reverts the stimulatory effect of angiotensin II on the proximal tubule Na(+)-ATPase activity via a A779-sensitive receptor. Regul. Pept. (2002) 103:17-22.
89. 2 activity and sodium transport by angiotensin-(1-7). Kidney Int. (1993) 44:932-936.
90. SANTOS RAS, SIMÕES E SILVA AC, KHOSLA MC et al.: Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension (1996) 27:875-884.
91. MAGALDI AJ, CESAR KR, ARAUJO M, SIMÕES E SILVA AC, SANTOS RAS: Angiotensin-(1-7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch. (2003) 447(2):223-230.
92. SIMÕES E SILVA AC, BELLO APC, BARACHO NCV, KHOSLA MC, SANTOS RAS: Diuresis and natriuresis produced by long term administration of a selective angiotensin-(1-7) antagonist in normotensive and hypertensive rats. Regul. Pept. (1998) 74:177-184.
93. VALLON V, HEYNE N, RICHTER K, KHOSLA MC, FECHTER K: [D-ALA7]-angiotensin 1-7 blocks renal actions of angiotensin 1-7 in the anesthetized rat. J. Cardiovasc. Pharmacol. (1998) 32(1):164-167.
94. WIEMER G, DOBRUCKI LW, LOUKA FR, MALINSKI T, HEITSCH H: AVE-0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension (2002) 40(6):847-852.
95. PINHEIRO SVB, SIMÕES E SILVA AC, SAMPAIO WO et al.: Nonpeptide AVE-0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension (2004) 44(4):490-496.
96. DIZ DI, PIRRO NT: Differential actions of angiotensin II and angiotensin-(1-7) on transmitter release. Hypertension (1992) 19(Suppl. 2):II41-II48.
97. JAISWAL N, DIZ DI, CHAPPELL MC, KHOSLA MC, FERRARIO CM: Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension (1992) 19:II49-II55.
98. TALLANT EA, JAISWAL N, DIZ DI, FERRARIO CM: Human astrocytes contain two distinct angiotensin receptor subtypes. Hypertension (1991) 18(1):32-39.
99. AMBUHL P, FELIX D, KHOSLA MC: [7-D-ALA]-angiotensin-(1-7): selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus. Brain Res. Bull. (1994) 35(4):289-291.
100. FONTES MAP, SILVA LC, CAMPAGNOLE-SANTOS MJ, KHOSLA MC, GUERTZENSTEIN PG, SANTOS RAS: Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors. Brain Res. (1994) 665(1):175-180.
101. NEVES LAA, SANTOS RAS, KHOSLA MC, MILSTED A: Angiotensin-(1-7) regulates the levels of angiotensin II receptor subtype AT1 mRNA differentially in a strain-specific fashion. Regul. Pept. (2000) 95:99-107.
102. WALTHER T, BALSCHUN D, VOIGT JP et al.: Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem. (1998) 273(19):11867-11873.
103. HARDING JW, COOK VI, MILLER-WING AV et al.: Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. Brain Res. (1992) 583(1-2):340-343.
104. METZGER R, BADER M, LUDWIG T, BERBERICH C, BUNNEMANN B, GANTEN D: Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett. (1995) 357(1):27-32.
105. CASTRO CH, SANTOS RAS, WALTHER T, ALENINA N, BADER M, ALMEIDA AP: Effects of genetic deletion of the G-protein-coupled receptor Mas on cardiac function during ischemia and reperfusion in the mouse isolated perfused heart. Hypertension (2004) 43(6):1350.
106. GEMBARDT F, WESTERMANN D, HERINGER-WALTHER S, SCHULTHEISS HP, TSCHÖPE C, WALTER T: Deficiency in the G protein-coupled receptor Mas leads to cardiomyopathy and demonstrates the importance of the endogenous ligand angiotensin-(1-7) for the cardiac function. Naunyn Schmiedebergs Arch. Pharmacol. (2003) 369(Suppl. 1):R68.
107. WALTHER T, WESSEL N, KANG N et al.: Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. Braz. J. Med. Biol. Res. (2000) 33(1):1-9.
108. SANTOS RAS, PASSAGLIO KT, PESQUERO JB, BADER M, SIMÕES E SILVA AC: Interactions between kinins and angiotensin-(1-7) in kidney and blood vessels. Hypertension (2001) 38:660-664.
109. DEDDISH PA, MARCIC B, JACKMANN HL, WANG H, SKIDGEL RA, ERDÖS EG: N-domain specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension (1998) 31:912-917.
110. ERDOS EG, JACKMAN HL, BROVKOVYCH V, TAN F, DEDDISH PA: Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J. Mol. Cell. Cardiol. (2002) 34(12):1569-1576.
111. MAHON JM, CARR RD, NICOL AK, HENDERSON IW: Angiotensin-(1-7) is an antagonist at the type I angiotensin II receptor. J. Hypertens. (1994) 12:1377-1381.
112. 2+ in mesangial cells. Eur. J. Pharmacol. (2001) 414:165-175.
113. VON BOHLEN UND HALBACH O, WALTHER T, BADER M, ALBRECHT D: Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J. Neurophysiol. (2000) 83:2012-2021.
114. ZHU Z, ZHONG J, ZHU S, LIU D, VAN DER GIET M, TEPEL M: Angiotensin-(1-7) inhibits angiotensin II-induced signal transduction. J. Cardiovasc. Pharmacol. (2002) 40:693-700.
115. CLARK MA, TALLANT EA, TOMMASI E, BOSCH S, DIZ DI: Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. J. Cardiovasc. Pharmacol. (2003) 41:276-283.
116. ABDALLA S, LOTHER H, QUITTERER U: AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature (2000) 407:94-98.
117. ABDALLA S, LOTHER H, ABDEL-TAWAB AM, QUITTERER U: The angiotensin II AT2 receptor is an AT1 receptor antagonist. J. Biol. Chem. (2001) 276:39721-39726.
118. KOSTENIS E, MILLIGAN G, CHRISTOPOULOS A et al.: G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation (2005) 111(14):1806-1813.
119. CLARK MA, TALLANT FA, DIZ DI: Downregulation of the AT1A receptor by pharmacologic concentrations of angiotensin-(1-7). J. Cardiovasc. Pharmacol. (2001) 37:437-448.
120. CLARK MA, DIZ DI, TALLANT EA: Angiotensin-(1-7) downregulates the angiotensin II type I receptor in vascular smooth cells. Hypertension (2001) 37:1141-1146.
121. MOURA-FAGUNDES CR: Perfil plasmático de angiotensinas durante o desenvolvimento da hipertensão renal tipo um-rim, um-clip em rato. Eeito do tratamento com losartan. Thesis ICB-UFMG, Belo horizonte MG, Brazil (1997).
122. CAMPBELL DJ, KRUM H, ESLER MD: Losartan increases bradykinin levels in hypertensive humans. Circulation (2005) 111(3):315-320.
123. CHAPPELL MC, MODRALL JG, DIZ DI, FERRARIO CM: Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. In: Contribution to Nephrology, Kidney and Blood Pressure Regulation. Suzuki H, Saruta T (Eds), Karger, Basel (2004) 143:77-89.